PRJNA769577
Effect of a new drug in EAE disease model of multiple sclerosis on the mice gut microbiome
Multiple sclerosis is associated with destruction of oligodendrocytes, demyelination and impaired remyelination. Disease modifying therapies available act mainly anti-inflammatory, neuroregenerative substances with potential remyelination-promoting effects are lacking. The impact of a new medicine that closes this gap on the gut microbiome has been studied.